Disease control in patients treated with naxitamab for refractory/relapsed high-risk neuroblastoma

被引：0
|
作者：
Mora, Jaume
Chan, Godfrey C.
Morgenstern, Daniel A.
Amoroso, Loredana
Nysom, Karsten
Faber, Joerg
Wingerter, Arthur
Bear, Melissa
Rubio-San-Simon, Alba
Tornoe, Karen
Koep, Sharif
During, Maria
Kushner, Brian H.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 17期
关键词：
D O I：
10.1158/1538-7445.PEDIATRIC24-B055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B055
引用
收藏
页数：3
相关论文
共 50 条
  • [21] GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
    Quintarelli, Concetta
    del Bufalo, Francesca
    Locatelli, Franco
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (24): : 2303 - 2304
  • [22] GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
    Del Bufalo, Francesca
    De Angelis, Biagio
    Caruana, Ignazio
    Del Baldo, Giada
    De Ioris, Maria A.
    Serra, Annalisa
    Mastronuzzi, Angela
    Cefalo, Maria G.
    Pagliara, Daria
    Amicucci, Matteo
    Li Pira, Giuseppina
    Leone, Giovanna
    Bertaina, Valentina
    Sinibaldi, Matilde
    Di Cecca, Stefano
    Guercio, Marika
    Abbaszadeh, Zeinab
    Iaffaldano, Laura
    Gunetti, Monica
    Iacovelli, Stefano
    Bugianesi, Rossana
    Macchia, Stefania
    Algeri, Mattia
    Merli, Pietro
    Galaverna, Federica
    Abbas, Rachid
    Garganese, Maria C.
    Villani, Maria F.
    Colafati, Giovanna S.
    Bonetti, Federico
    Rabusin, Marco
    Perruccio, Katia
    Folsi, Veronica
    Quintarelli, Concetta
    Locatelli, Franco
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (14): : 1284 - 1295
  • [23] Disease control intervals in high-risk neuroblastoma
    Santana, Victor M.
    Furman, Wayne L.
    McGregor, Lisa M.
    Billups, Catherine A.
    CANCER, 2008, 112 (12) : 2796 - 2801
  • [24] The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial
    Mora, Jaume
    Chan, Godfrey C. F.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa K.
    Rubio-San-Simon, Alba
    de las Heras, Blanca Martinez
    Tornoe, Karen
    Duering, Maria
    Kushner, Brian H.
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [25] Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201
    Mora, J.
    Bear, M.
    Chan, G.
    Morgenstern, D. A.
    Nysom, K.
    Tornoe, K.
    Losic, N.
    Kushner, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S833 - S833
  • [26] Allogeneic transplantation for patients with high-risk or refractory neuroblastoma.
    Driscoll, T. A.
    Martin, P. L.
    Moffet, J.
    Daniel, M.
    Page, K.
    Parikh, S.
    Prasad, V.
    Szabolcs, P.
    Kurtzberg, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Prognosis of Patients with Relapsed, High-risk Neuroblastoma: A Single Center Experience
    Yamada, Yuji
    Kiyotani, Chikako
    Shioda, Yoko
    Osumi, Tomoo
    Kato, Motohiro
    Tomizawa, Daisuke
    Terashima, Keita
    Hishiki, Tomoro
    Fujino, Akihiro
    Kanamori, Yutaka
    Fuji, Hiroshi
    Yoshioka, Takako
    Miyazaki, Osamu
    Matsumoto, Kimikazu
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S41 - S42
  • [28] EFFICACY OF NAXITMAB IN REFRACTORY HIGH-RISK NEUROBLASTOMA
    Mora, Jaume
    Chan, Godfrey Chi Fung
    Morgenstern, Daniel
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio San Simon, Alba
    Kushner, Brian
    Tornoe, Karen
    Christensen, Rene
    PEDIATRIC BLOOD & CANCER, 2023, 70
  • [29] Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone
    Sokol, Elizabeth
    Haut, Paul R.
    Gosiengfiao, Yasmin
    Feinstein, Kate
    Pytel, Peter
    Cohn, Susan L.
    PEDIATRIC BLOOD & CANCER, 2013, 60 (03) : 512 - 514
  • [30] International, Multicenter Phase II Trial With Humanized Anti-GD2 Monoclonal Antibody Naxitamab for Treatment of Refractory/Relapsed High-Risk Neuroblastoma: Efficacy and Safety Data
    Mora, J.
    Chan, G.
    Morgenstern, D.
    Nysom, K.
    Bear, M.
    Dalby, L. W.
    Lisby, S.
    Kushner, B.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S294 - S294
12345